These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21851800)

  • 41. The US drug safety system: role of the pharmaceutical industry.
    Gibson BR; Suh R; Tilson H
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Signal detection in post-marketing surveillance for controlled substances.
    Dasgupta N; Schnoll SH
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S33-41. PubMed ID: 19616902
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of exposure accrual on sequential postmarket evaluations: a simulation study.
    Maro JC; Brown JS
    Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1184-91. PubMed ID: 22020903
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Post marketing surveillance of new drugs. Patient safety in the hands of GPs.
    Marley JE
    Aust Fam Physician; 1989 Sep; 18(9):1133-5. PubMed ID: 2590077
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Thinking on risk assessment and risk management of post-marketing Chinese medicine].
    Yu X; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(2):262-4. PubMed ID: 22737865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk Management Plans: are they a tool for improving drug safety?
    Frau S; Font Pous M; Luppino MR; Conforti A
    Eur J Clin Pharmacol; 2010 Aug; 66(8):785-90. PubMed ID: 20577875
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns.
    Holm JEJ; Ruppert JG; Ramsden SD
    Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Harmonisation of the Marketing Authorisation Application dossier: perspectives due to harmonised requirements. Assessing Rules and the Common Technical Document].
    Menges K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):748-56. PubMed ID: 18584104
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Non-interventional post-authorisation studies in Spain: justification and basis of a new regulation].
    De La Fuente Honrubia C; De Abajo Iglesias FJ; García Del Pozo J; Vargas Castrillón E
    Med Clin (Barc); 2010 May; 134(13):605-11. PubMed ID: 20304440
    [No Abstract]   [Full Text] [Related]  

  • 50. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.
    Tsintis P; La Mache E
    Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Case histories in pharmaceutical risk management.
    McCormick CG; Henningfield JE; Haddox JD; Varughese S; Lindholm A; Rosen S; Wissel J; Waxman D; Carter LP; Seeger V; Johnson RE
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S42-55. PubMed ID: 19767156
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessments.
    McGettigan P; Alonso Olmo C; Plueschke K; Castillon M; Nogueras Zondag D; Bahri P; Kurz X; Mol PGM
    Drug Saf; 2019 Nov; 42(11):1343-1351. PubMed ID: 31302896
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biosimilars: from technical to pharmacoeconomic considerations. 30th Rencontres Nationales de Pharmacologie et Recherche clinique pour l'Innovation et l'Evaluation des Technologies de Santé. Tables rondes.
    Girault D; Trouvin JH; Blachier-Poisson C; Gary F; Laloye D; ; Bergmann JF; Casadevall N; Delval C; De Sahb Berkovitch R; Fagon JY; Gersberg M; Lassale C; Lechat P; Le Jeunne C; Montastruc JL; Prugnaud JL; Ratignier-Carbonneil C; Rey-Coquais C;
    Therapie; 2015; 70(1):37-55. PubMed ID: 25679193
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Egberts TC; Blackburn S; Persson I; Leufkens HG
    Drug Saf; 2009; 32(12):1175-87. PubMed ID: 19916584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Description of postauthorisation observational prospective studies with drugs in the valencian region between 2010 and 2015. Factors associated with their authorisation.].
    Grau Rubio MA; Gómez-Pajares F; Izquierdo María R; Zapater Hernández P; Fernández Martínez S
    Rev Esp Salud Publica; 2017 Nov; 91():. PubMed ID: 29171462
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systems-based approach to risk management.
    Menighan TE
    J Am Pharm Assoc (2003); 2005; 45(2):116. PubMed ID: 15868747
    [No Abstract]   [Full Text] [Related]  

  • 57. [Technical specifications for post-marketing pharmacoeconomic evaluation of Chinese medicine (draft version for comments)].
    Xie YM; Wang X; Wang N; Chang YP
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2925-9. PubMed ID: 24471305
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Post-marketing drug safety-risk management plan(RMP)].
    Ezaki A; Hori A
    Gan To Kagaku Ryoho; 2013 Mar; 40(3):279-84. PubMed ID: 23507587
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Drug registries: post-marketing evaluation of the benefit-risk profile and promotion of appropriateness. The regional point of view].
    Martelli L; Venegoni M
    Recenti Prog Med; 2013 Jun; 104(6):272-4. PubMed ID: 23801232
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Experimental testing of centrally authorised medicinal products. The CAP programme].
    Giess S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1169-72. PubMed ID: 25159224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.